TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Efficacy (CR+PR rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and urine concentrations of formoterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in body height per annuum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pethidine requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of signal modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of glenoid loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absence of radiolucent lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AUC of model based on analyzing behavioral dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postoperative renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: WHODAS 2.0 completion rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bispectral index (BIS) monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carpal Tunnel Syndrome Assessment Questionnaire- function scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in pre-dialysis serum phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse Post-op Events Related to the Repair and Plating System
Endpoint domain: Adverse events/effects
Primary endpoint: Physical Functioning Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Role Limitations - Physical Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Role Limitations - Emotional Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Vitality Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Emotional Well-being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Bacterial growth in the root canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Who Reported Abstinent From Opioids For the Previous 7 Days at Month 24
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Who Reported Abstinent From Opioids For the Previous 28 Days at Month 24
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Taste recognition threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste intensity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance Quality Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immune infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cellular senescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body weight from baseline to post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body weight from post-intervention to follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AM-PAC Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Rey Auditory Verbal Learning Test Sum of Trials 1-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Resting Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Reporting Serious Adverse Event (SAEs) and SAE(s) Causally Related to Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Medically Significant Conditions
Endpoint domain: Adverse events/effects
Primary endpoint: QTcNi change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognition as measured by neurocognitive testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognition as measured by advanced resting-state functional connectivity MRI (rsfcMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive recovery in children determined by multiplexed analyses of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain function as measured by neurocognitive testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain function as measured by advanced resting-state functional connectivity MRI (rsfcMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects With Any Solicited Local and General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Unsolicited Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Biochemical Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Hematological Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and percentage of eligible patients discharged on optimal therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients able to undergo reaction-free desensitizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants reaching HbA1c<7% and HbA1c<6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in body weight from baseline to 3, 6, 9 and 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in risk of hypoglycemia from baseline to 3, 6, 9 and 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of bryostatin-1
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Change in Falls Efficacy Scale International test (FES I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NRS change from Baseline NRS at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI change from Baseline ODI at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRLS item 10 score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: BDI-II total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Plasma Viral Load at Week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Plasma Viral Load at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of undiagnosed chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Acculturative Stress Scale for Chinese Students (ASSCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of intrapatient intermetastatic heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of neuroendocrine lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of eligible patients for PSMA-RLT or OCTREOTATE-RLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STI infections (GC and CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Device Associated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: total Western Ontario McMaster (WOMAC) OA index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalogram signal comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overnight Mean Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PCR negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Disease relapse as diagnosed by fecal calprotectin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average Daily Normalized Off Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of adjuvant chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of genetically confirmed new FH cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Weight at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in BMI at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in HbA1c at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Fasting Glucose at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to First On-trial Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stricture dilatation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with AEs Leading to Dose Reduction, Treatment Interruption and Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: clinical complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in steady-state plasma concentrations of psychotropic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in shoulder pain and disability index (SPADI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Definition Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalized Change in Definition Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shock Reduction Programming Adoption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage Change in Positive Left Ventricular dP/dt Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients Achieving Therapeutic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of arrival in shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on cellular and molecular profile of atopic dermatitis skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of successful analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Acceptable Residual WBC Level in Platelet Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients enrolled for HIV prevention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SpHb Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpHb Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracortical circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spinal circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood BDNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequencies of gaps in care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants on TCZ Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pure tone audiometry test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pain assessed by NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 Local Skin Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Mean neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in parent motivation to implement injury prevention strategies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parent knowledge of injury prevention practices
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in orbitofrontal cortex activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: severity of radiation dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change from Baseline for mean reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRNT80 ≥ 1:40 after primary series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PRNT80 ≥ 1:40 after 6-month mandatory booster dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median duration of PRNT80 ≥ 1:40 in initial responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse Event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Level of agitation at the time of extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocal Tremor Scoring System (VTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Daytime activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure and/or Product Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Central Apnea-hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory Arousal Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the number of drinks and frequency of drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the severity of alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatal and Nonfatal Ischemic Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Receipt of any analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wheelchair Skills Test (WST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Identified With Malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion of protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pressure-pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain catastrophizing scale (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interference score using K-CWST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Montreal Cognitive Assessment Korean (MOCA-K)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of complicated grief 4 months after death
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of complicated grief 6 months after death
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of complicated grief 12 months after death
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes from baseline intrahepatic fat (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lead safety
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events and dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Ability of the EndoRotor to resect lesions without concomitant use of other resection modalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of serious adverse events related to the EndoRotor device
Endpoint domain: Adverse events/effects
Primary endpoint: Local Tumor Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Heart Rate Variability Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of CD19-targeted T cell methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of successful treatments of bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragmatic mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete Response for HSIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Force generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Eczema Area and Severity Index (EASI)-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: anti-tumor efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Factor VIII level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dysgeusia (UMAMI Perception)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysgeusia (SWEET Perception)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysgeusia (BITTER Perception)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classroom Behavior Observations
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: sFlt-1 clearance kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of students consenting to donation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change From Baseline in V-Scale Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Systolic Arterial Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Arterial Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Arterial Pressure (MBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline of general developmental
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of body function & structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Sensory and Perceptual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from baseline of Visual Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful first attempt intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Whole Body Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Brown Adipose Tissue Volume at First Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Brown Adipose Tissue Volume at Second Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of children with moderate anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Unified Parkinson Disease Rating Scale (UPDRS) III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety measured by SUSARs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of detection of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes